Increased STX3 Transcript and Protein Levels Were Associated with Poor Prognosis in Two Independent Cohorts of Esophageal Squamous Cell Carcinoma Patients

Overview

Journal Cancer Med

Specialty Oncology

Date 2023 Nov 28

PMID 38014487

Authors

Takahiro Shinozuka

Mitsuro Kanda

Yusuke Sato

Dai Shimizu

Chie Tanaka

Shinichi Umeda

Yoshikuni Inokawa

Norifumi Hattori

Masamichi Hayashi

Goro Nakayama

Yasuhiro Kodera

Affiliations

Soon will be listed here.

Abstract

Background: Some conventional prognostic biomarkers for esophageal squamous cell carcinoma (ESCC) have the disadvantage that they have only been investigated at the level of either mRNA or protein levels or only in individual cohorts. Associations between Syntaxin 3 (STX3) expression and malignancy have been reported in several tumor types but not in ESCC. Here, we investigated the levels of both STX3 mRNA and protein, and its prognostic potential in two independent cohorts of patients with ESCC.

Methods: STX3 mRNA levels were examined in surgical specimens by quantitative PCR in a cohort that included 176 ESCC patients. STX3 protein levels were investigated in surgically resected ESCC tissues by immunohistochemistry using tissue microarrays in a different cohort of 177 ESCC patients. Correlations were analyzed between the expression of STX3 mRNA and protein with clinicopathological factors and long-term prognosis.

Results: Quantitative PCR indicated a significant association between high level of STX3 mRNA expression and lymph node involvement, pathological stage, and poor overall survival. The multivariate analysis demonstrated that high STX3 mRNA expression was independently associated with poor overall survival outcomes. Immunohistochemistry revealed that STX3 protein expression in ESCC tissues and high STX3 protein expression were also significantly correlated with unfavorable overall survival.

Conclusions: Overexpression of STX3 mRNA and protein may serve as potential prognostic biomarkers for ESCC patients.

Citing Articles

Increased STX3 transcript and protein levels were associated with poor prognosis in two independent cohorts of esophageal squamous cell carcinoma patients.

Shinozuka T, Kanda M, Sato Y, Shimizu D, Tanaka C, Umeda S Cancer Med. 2023; 12(24):22185-22195.

PMID: 38014487 PMC: 10757105. DOI: 10.1002/cam4.6770.

References

Shinozuka T, Kanda M, Sato Y, Shimizu D, Tanaka C, Umeda S . Increased STX3 transcript and protein levels were associated with poor prognosis in two independent cohorts of esophageal squamous cell carcinoma patients. Cancer Med. 2023; 12(24):22185-22195. PMC: 10757105. DOI: 10.1002/cam4.6770. View

Kanda M, Shimizu D, Sawaki K, Nakamura S, Umeda S, Miwa T . Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer. Mol Cancer. 2020; 19(1):131. PMC: 7448342. DOI: 10.1186/s12943-020-01251-0. View

Umeda S, Kanda M, Shimizu D, Nakamura S, Sawaki K, Inokawa Y . Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells. Gastric Cancer. 2022; 25(3):558-572. DOI: 10.1007/s10120-022-01284-y. View

Du J, Liu X, Wu Y, Zhu J, Tang Y . Essential role of STX6 in esophageal squamous cell carcinoma growth and migration. Biochem Biophys Res Commun. 2016; 472(1):60-7. DOI: 10.1016/j.bbrc.2016.02.061. View

Shimizu D, Koike M, Kanda M, Sonohara F, Hattori N, Hayashi M . Newly developed primary malignancies in long-term survivors who underwent curative esophagectomy for squamous cell carcinoma of the esophagus. Surg Today. 2020; 51(1):153-158. DOI: 10.1007/s00595-020-02072-w. View

Day P, Riggs K, Hasan N, Corbin D, Humphrey D, Hu C . Syntaxins 3 and 4 mediate vesicular trafficking of α5β1 and α3β1 integrins and cancer cell migration. Int J Oncol. 2011; 39(4):863-71. DOI: 10.3892/ijo.2011.1101. View

Giovannone A, Winterstein C, Bhattaram P, Reales E, Low S, Baggs J . Soluble syntaxin 3 functions as a transcriptional regulator. J Biol Chem. 2018; 293(15):5478-5491. PMC: 5900775. DOI: 10.1074/jbc.RA117.000874. View

Ueda S, Kanda M, Sato Y, Baba H, Nakamura S, Sawaki K . Chromobox 2 Expression Predicts Prognosis After Curative Resection of Oesophageal Squamous Cell Carcinoma. Cancer Genomics Proteomics. 2020; 17(4):391-400. PMC: 7367605. DOI: 10.21873/cgp.20198. View

Baba H, Kanda M, Sawaki K, Nakamura S, Ueda S, Shimizu D . SLC7A9 as a Potential Biomarker for Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2021; 29(4):2699-2709. DOI: 10.1245/s10434-021-11001-1. View

10.

Sato Y, Motoyama S, Wakita A, Kawakita Y, Liu J, Nagaki Y . TLR3 expression status predicts prognosis in patients with advanced thoracic esophageal squamous cell carcinoma after esophagectomy. Am J Surg. 2018; 216(2):319-325. DOI: 10.1016/j.amjsurg.2018.01.038. View

11.

Kanda M, Koike M, Shimizu D, Tanaka C, Hattori N, Hayashi M . Characteristics Associated with Nodal and Distant Recurrence After Radical Esophagectomy for Squamous Cell Carcinoma of the Thoracic Esophagus. Ann Surg Oncol. 2020; 27(9):3195-3205. DOI: 10.1245/s10434-020-08433-6. View

12.

Shinozuka T, Kanda M, Shimizu D, Tanaka C, Inokawa Y, Hattori N . Prognostic Value of a Modified Albumin-Bilirubin Score Designed for Patients with Esophageal Squamous Cell Carcinoma After Radical Resection. Ann Surg Oncol. 2022; 29(8):4889-4896. DOI: 10.1245/s10434-022-11654-6. View

13.

Xiao Z, Jia Y, Jiang W, Wang Z, Zhang Z, Gao Y . FOXM1: A potential indicator to predict lymphatic metastatic recurrence in stage IIA esophageal squamous cell carcinoma. Thorac Cancer. 2018; 9(8):997-1004. PMC: 6068428. DOI: 10.1111/1759-7714.12776. View

14.

Baba H, Kanda M, Sato Y, Sawaki K, Shimizu D, Koike M . Expression and Malignant Potential of B4GALNT4 in Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2020; 27(9):3247-3256. DOI: 10.1245/s10434-020-08431-8. View

15.

Nan H, Han L, Ma J, Yang C, Su R, He J . STX3 represses the stability of the tumor suppressor PTEN to activate the PI3K-Akt-mTOR signaling and promotes the growth of breast cancer cells. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(5 Pt A):1684-1692. DOI: 10.1016/j.bbadis.2018.01.031. View

16.

Yusupbekov A, Kanda M, Usmanov B, Tuychiev O, Baymakov S, Sakamoto J . Surveillance of Esophageal Cancer in the Republic of Uzbekistan from 2000 to 2018. Asian Pac J Cancer Prev. 2020; 21(8):2281-2285. PMC: 7771931. DOI: 10.31557/APJCP.2020.21.8.2281. View

17.

Miyoshi J, Zhu Z, Luo A, Toden S, Zhou X, Izumi D . A microRNA-based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study. Mol Cancer. 2022; 21(1):44. PMC: 8832722. DOI: 10.1186/s12943-022-01507-x. View

18.

Baba H, Kanda M, Sawaki K, Umeda S, Miwa T, Shimizu D . PRAME as a Potential Biomarker for Liver Metastasis of Gastric Cancer. Ann Surg Oncol. 2019; 27(6):2071-2080. DOI: 10.1245/s10434-019-07985-6. View

19.

Chen Y, Shen L, Chen B, Han X, Yu Y, Yuan X . The predictive prognostic values of , , , , , and in lung cancer. Ann Transl Med. 2021; 9(10):843. PMC: 8184469. DOI: 10.21037/atm-21-1392. View

20.

Kinghorn K, Gill A, Marvin A, Li R, Quigley K, Singh S . A defined clathrin-mediated trafficking pathway regulates sFLT1/VEGFR1 secretion from endothelial cells. Angiogenesis. 2023; 27(1):67-89. PMC: 10881643. DOI: 10.1007/s10456-023-09893-6. View